🇺🇸 FDA
Patent

US 9757366

Methods for the treatment of parkinson's disease psychosis using pimavanserin

granted A61KA61K31/12A61K31/13

Quick answer

US patent 9757366 (Methods for the treatment of parkinson's disease psychosis using pimavanserin) held by ACADIA Pharmaceuticals Inc. expires Mon Sep 07 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
ACADIA Pharmaceuticals Inc.
Grant date
Tue Sep 12 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 07 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
6
CPC classes
A61K, A61K31/12, A61K31/13, A61K31/137, A61K31/165